Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBITDA (2021 - 2025)

Verrica Pharmaceuticals has reported EBITDA over the past 5 years, most recently at -$7.2 million for Q4 2025.

  • Quarterly results put EBITDA at -$7.2 million for Q4 2025, up 36.97% from a year ago — trailing twelve months through Dec 2025 was -$12.2 million (up 81.52% YoY), and the annual figure for FY2025 was -$12.2 million, up 81.52%.
  • EBITDA for Q4 2025 was -$7.2 million at Verrica Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over the last five years, EBITDA for VRCA hit a ceiling of $1.6 million in Q3 2025 and a floor of -$24.8 million in Q3 2023.
  • Median EBITDA over the past 5 years was -$9.9 million (2021), compared with a mean of -$10.2 million.
  • Biggest five-year swings in EBITDA: crashed 21118.64% in 2023 and later soared 109.93% in 2025.
  • Verrica Pharmaceuticals' EBITDA stood at -$9.6 million in 2021, then skyrocketed by 38.3% to -$5.9 million in 2022, then plummeted by 316.97% to -$24.6 million in 2023, then skyrocketed by 53.64% to -$11.4 million in 2024, then surged by 36.97% to -$7.2 million in 2025.
  • The last three reported values for EBITDA were -$7.2 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.